Clinical Study: References and Footnotes

1. Goldberg RB, Einhorn D, Lucas CP, et al. A randomized placebo-controlled trial of repaglinide in the treatment of type 2 diabetes. Diabetes Care. 1998;21:1897-1903.
2. PRANDIN^® Prescribing Information, Novo Nordisk Pharmaceuticals, Inc.
3. Moses R, Slobodniuk R, Boyages S, et al. Effect of repaglinide addition to metformin monotherapy on glycemic control in patients with type 2 diabetes. Diabetes Care. 1999;22:119-124.
4. Madsbad S, Kilhovd B, Lager I, Mustajoki P, Dejgaard A. Comparison between repaglinide and glipizide in type 2 diabetes mellitus: a one-year multicentre study. Diabetic Med. 2001; 18:395-401.
5. Marbury T, Huang W-C, Strange P, Lebovitz H. Repaglinid vs. glyburide: a one-year comparison trial. Diabetes Res Clin Pract. 1999;43:155-166.
6. The American Association of Clinical Endocrinologists Medical Guidelines for the Management of Diabetes Mellitus: The AACE System of Intensive Diabetes Self-Management — 2002 Update. Developed by the American Association of Clinical Endocrinologists and the American College of Endocrinology — 2002. Endocrine Practice. 2002;8(January/February Suppl. 1):40-82.
7. DeFronzo RA. Pharmacologic therapy for type 2 diabetes mellitus. Ann Intern Med. 1999;131:281-303.
8. Data on file, Novo Nordisk Pharmaceuticals, Inc.

All product information on this site is for US residents only.